Premium
The addition of CD 20 monoclonal antibodies to lenalidomide improves response rates and survival in relapsed/refractory patients with chronic lymphocytic leukaemia relative to lenalidomide monotherapy – the MD Anderson Cancer Center experience
Author(s) -
Thompson Philip A.,
Rozovski Uri,
Keating Michael J.,
Stingo Francesco,
Smith Susan C.,
Wierda William G.,
Falchi Lorenzo,
O'Brien Susan M.,
Estrov Zeev,
Burger Jan A.,
Ferrajoli Alessandra
Publication year - 2015
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.13377
Subject(s) - lenalidomide , medicine , ofatumumab , rituximab , chronic lymphocytic leukemia , neutropenia , gastroenterology , oncology , multiple myeloma , chemotherapy , lymphoma , leukemia